... to in the content or advertisements. Memory Attention Cognition Cognitive test battery MMSE Aging Alzheimer's disease Parkinson's disease Factor analysis CANTAB ...

...Linda Bierer; Paul S. Aisen; Michael Davidson; Theresa M. Ryan; James Schmeidler; Kenneth L. Davis To assess the feasibility of one approach to combined cholinergic/noradrenergic treatment in Alzheimer's disease, ten patients were enrolled in a 2-week placebo-controlled study of oral physostigmine...

...C.R. Harrington; R.H. Perry; E.K. Perry; J. Hurt; I.G. McKeith; M. Roth; C.M. Wischik We have used biochemical assays to examine cingulate and occipital cortices from age-matched cases of Alzheimer's disease (AD; n = 12), senile dementia of the Lewy body type (SDLT; n = 13), Parkinson's disease (PD...

...R.A. Armstrong The density of senile plaques (SP) and neurofibrillary tangles (NFT) was estimated at post-mortem in areas B17 and B18 of the visual cortex in 18 Alzheimer's disease (AD) cases which varied in disease onset and duration. The density of SP in B17 and NFT in B17 and B18 declined...

...C.R. Harrington; R.H. Perry; E.K. Perry; J. Hurt; I.G. McKeith; M. Roth; C.M. Wischik We have used biochemical assays to examine cingulate and occipital cortices from age-matched cases of Alzheimer's disease (AD; n = 12), senile dementia of the Lewy body type (SDLT; n = 13), Parkinson's disease (PD...

...Lutz M. Drach; Jürgen Bohl; Hans-H. Goebel Lipofuscin, the age pigment, is of interest in Alzheimer's disease because of its property to accumulate in neurons and because of the hypothesis that Alzheimer's dementia is a kind of premature ageing. The amount of intraneuronal lipofuscin...

...Jan Balldin; Kaj Blennow; Görel Bråne; C.G. Gottfries; Ingvar Karlsson; Björn Regland; Anders Wallin In 40 patients with Alzheimer's disease (AD, <65 years), 56 patients with senile dementia of the Alzheimer type (SDAT, ≥65 years) and 45 patients with vascular dementia (VAD), basal cortisol...

... disease, but its prevalence in non-Alzheimer dementias in Caucasian populations is unknown. We found that the frequency of the apoE Ε4 allele was 0.45 in 93 Alzheimer's disease patients, 0.46 in 23 vascular dementia patients, 0.31 in 13 dementia of the frontal type patients, and 0.18 in 51 elderly...

.... Alzheimer's disease Lewy body dementia Attention Neuropsychological tests Microcomputer Original Research Article Dementia 1992;3:350-354 Aijim Sahgala Peter H. Galloway3 Ian G. McKeitha - b James A. Edwardsona Stephen Lloyd3 a MRC Neurochemical Pathology Unit. Newcastle General Hospital...

...Donald L. Bliwise; Jerome A. Yesavage; Jared R. Tinklenberg Nocturnal exacerbation of disruptive behaviors has long been recognized as a common occurrence in Alzheimer's disease (AD), however the basis for such sleep disruption is poorly understood. In this study, caregivers of 60 patients...

...Stefan Pollmann; Martin Haupt; Barbara Romero; Alexander Kurz In a longitudinal study of 90 out-patients with a clinical diagnosis of Alzheimer's disease (ICD 10) we found 11 patients with isolated cognitive symptoms that remained stable from baseline to 1-year follow-up. Two patients showed...

... of Alzheimer's disease (AD) and 4 matched controls. The quantitative assessment of the somatostatin and neuropeptide Y immunoreactive cell perikarya was conducted on regularly spaced sections covering the span of the whole hippocampus and parahippocampal cortex. The estimated total number of somatostatin...

...Anders Wallin; Kaj Blennow In 68 patients (mean age 71 ± 8 years) with clinically diagnosed Alzheimer's disease (AD), the presence of various neurologic motor signs was investigated, both in the total patient sample and in subgroups with early-onset AD (onset before 65 years of age; n = 30...

... of full complement activation in diffuse plaques, which greatly predominate in the Alzheimer's cerebellum, may underlie the relative paucity of cerebellar pathology and clinical symptomatology in Alzheimer's disease. © 1992 S. Karger AG, Basel 1992 Copyright / Drug Dosage / Disclaimer Copyright: All...

...Alexander Kurz; Martin Haupt; Stefan Pollmann; Barbara Romero A sample of 90 patients with mild or moderate dementia in Alzheimer's disease was examined for subtypes within the cognitive phenomenology and course of the disorder. Language, memory, praxia, and perception were selected as symptom...

... of Alzheimer's disease (AD) and 4 matched controls. The quantitative assessment of the somatostatin and neuropeptide Y immunoreactive cell perikarya was conducted on regularly spaced sections covering the span of the whole hippocampus and parahippocampal cortex. The estimated total number of somatostatin...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Deprenyl Dopamine Monoamine oxidase B inhibitor Depression Parkinson's disease Alzheimer's disease IT 342 Kabins...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Deprenyl Dopamine Monoamine oxidase B inhibitor Depression Parkinson's disease Alzheimer's disease Review Dementia...

...J.P. Brion; M.E. Cheetham; A.M. Couck; J. Flament-Durand; D.P. Hanger; B.H. Anderton A cDNA encoding epitopes present in paired helical filaments (PHF) in Alzheimer's disease has been characterized by DNA sequencing and by immunochemical analysis of the encoded recombinant protein fragment...

... are living today. In preparation for a study of Alzheimer's disease (AD) in this Registry, we investigated 829 members of pairs living in North and South Carolina, Virginia, in the District of Columbia, and Maryland. A brief telephone interview for cognitive symptoms was administered to 678 (91.4%) of 742...